Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

about

A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).

P2860

Q33386694-004D57A9-4231-4A89-8D14-11D6047CBC6A Q37214290-6FC75032-CCEF-41A3-8E3E-8AC13A426508

P2860

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

Item

http://www.wikidata.org/entity/Q35987726

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

@ast

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

@en

type

Item

label

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

@ast

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

@en

prefLabel

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

@ast

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

@en

P1476

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

@en

P2093

Syma Iqbal

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

Clinical pharmacokinetics of capecitabine.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.

Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.

Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.

Capecitabine-induced potentiation of warfarin.

P304

947-955

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.4.6.947

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Heinz-Josef Lenz

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15606325

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

about

P2860

P2860

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921